- Home
- IPEX vs GNLX Comparison
IPEX vs GNLX Comparison
Compare IPEX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$10.60
HOLD
Current Price
$2.58
Company Overview
Basic Information| Metric | IPEX | GNLX |
|---|---|---|
| Founded | 2024 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.9M | 123.1M |
| IPO Year | 2024 | 2022 |
Fundamental Metrics
Financial Performance| Metric | IPEX | GNLX |
|---|---|---|
| Price | $10.60 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 27.7K | ★ 362.0K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.25 | $2.29 |
| 52 Week High | $10.70 | $8.54 |
Technical Indicators
Market Signals| Indicator | IPEX | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.47 | 41.96 |
| Support Level | $10.42 | $2.33 |
| Resistance Level | $10.70 | $2.98 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 66.67 | 7.59 |
Price Performance
Historical Comparison IPEX
GNLX
About IPEX Inflection Point Acquisition Corp. V Class A Ordinary Shares
Inflection Point Acquisition Corp V is a blank check company.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.